AMRI fetches $922M in the latest CRO private equity buyout
There’s another private equity deal to report on from the CRO front.
Albany, NY-based AMRI $AMRI announced Tuesday morning that it is being bought out for $922 million by The Carlyle Group and GTCR.
The buyout comes at $21.75 per share, which is a weighted average of 60 days trading ahead of the first reports about the brewing deal that first emerged on April 5th.
There have been a string of CRO buyouts and mergers over the past few years, with many of these deals aimed at consolidating a globally fractured industry as drug developers large and small look to outside contractors to do much of the heavy lifting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.